Country of origin: UK
Specialists should not stop prescribing sunitinib for people who were already taking it when the guidance was issued. These people should be able to carry on taking sunitinib until they and their specialist decide that it is the right time to stop treatment.
NICE has been appraising the use of bevacizumab, sorafenib, sunitinib and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma.
Following the independent advisory Committee meeting on 14 January 2009 NICE has decided to split this appraisal in two in order to get guidance out to the NHS as quickly as possible.
NICE is also appraising the use of bevacizumab, sorafenib and temsirolimus for first-line treatment options for advanced and/or metastatic renal cell carcinoma and the two drugs also licensed for second-line treatment of advanced or metastatic renal cell carcinoma, sorafenib and sunitinib, guidance is expected to be published later this year.
The guidance is available online.
Manual for Cancer Services: Chemotherapy Measures October 2018
Sublux radiology app for all medical providers October 2018
Study finds HPV from Oral Sex is linked to Throat Cancer September 2018
Asian-language cancer information resource September 2018
inPractice® Oncology September 2018
Cancer System Performance August 2018